Track 14: Cancer, Malaria & TB Vaccines
Malaria keeps on guaranteeing an expected 2 to 3 million lives every year and to represent untold dismalness in the around 300 to 500 million individuals contaminated yearly. Jungle fever is viewed as a reappearing malady, due to a great extent to the spread of medication safe parasite strains, rot of medicinal services framework and challenges in executing and keeping up vector control programs in many creating nations. Four types of protozoan parasites cause jungle fever in people: Plasmodium falciparum, P. vivax, P. malaria, and P. ovale. P. falciparum is liable for most of passing’s and the vast majority of the extreme types of sickness, including cerebral jungle fever. 2 billion individuals inactively tainted with M. tuberculosis 5-10% tainted individuals progress to sickness 9 million new TB cases every year 1.5 million TB passings every year Equivalent to 20 traveller flying machine crashes every day. TB is transmitted by grown-ups with citatory sickness HIV tainted individuals worry about more prominent concern of ailment. Most elevated danger of movement from TB contamination to dynamic infection, and most exceedingly terrible TB horribleness and mortality, contrasted with more established youngsters and grown-ups.
- AS01 Vaccine
- RTS,S
Related Conference of Track 14: Cancer, Malaria & TB Vaccines
9th International Conference on Vaccines, Immunology and Clinical Trials
Track 14: Cancer, Malaria & TB Vaccines Conference Speakers
Recommended Sessions
- Track 01: Vaccines
- Track 02: Pediatric Vaccines
- Track 03: HIV Vaccines
- Track 04: Toxoid Vaccines
- Track 05: DNA & Synthetic Vaccines
- Track 06: Vaccines for Pregnant Women
- Track 07: Pediatric Vaccination
- Track 08: Zika Virus Vaccines
- Track 09: Vaccines for Unconventional Diseases
- Track 10: Vaccine Production & Development
- Track 11: Human Vaccines Against Infectious Diseases
- Track 12: Combination & Conjugate Vaccines
- Track 13: Vaccine Safety & Efficacy
- Track 14: Cancer, Malaria & TB Vaccines
- Track 15: RDT in Antibiotic Research
- Track 16: Side-effects of Vaccines
- Track 17: Vaccines Manufacturing Technologies
- Track 18: Vaccines Research and Clinical Trails
- Track 19: New Trends in Vaccines Development
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (France)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (France)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (France)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (France)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (France)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (France)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (France)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (France)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (France)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (France)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (France)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (France)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (France)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (France)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Veterinary Vaccines - Euro Vaccines 2025 (France)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (France)